# Xenotransplantation in Nephrology: A Narrative Review

## TL;DR

Xenotransplantation using genetically modified pig kidneys could address the shortage of human organs for kidney transplants.

## Contribution

This paper reviews recent scientific and clinical advancements in xenotransplantation for kidney disease.

## Key findings

- Genetic engineering and immunosuppression have made xenotransplantation a feasible solution for ESKD.
- Clinical trials are beginning, but long-term outcomes and societal impact remain uncertain.
- Challenges include cross-species infections and ethical concerns about scaling porcine organ donation.

## Abstract

End-stage kidney disease (ESKD) is a global health challenge, with kidney transplant demand outstripping supply. Allotransplantation remains the gold standard for treatment but organ scarcity leads to prolonged waiting times and high mortality. Xenotransplantation, using genetically modified porcine kidneys, offers a novel and potentially sustainable solution. Genetic engineering and immunosuppression advances have enabled xenotransplantation to transition from a theoretical possibility to feasible solution. This review explores the evolution of xenotransplantation, the scientific advancements in overcoming immunological barriers, and emerging clinical data. Furthermore, we discuss emerging approaches such as central immune tolerance induction, the ongoing risks of cross-species infection, and the ethical and environmental considerations inherent to scaling up porcine organ donation. With the commencement of the first formal clinical trials, progress in the field could transform kidney transplantation, though questions remain regarding long-term outcomes and societal impact.